Search Results

You are looking at 1 - 10 of 182 items for :

  • bone formation and resorption x
  • All content x
Clear All
Free access

Kotaro Azuma, Stephanie C Casey, Masako Ito, Tomohiko Urano, Kuniko Horie, Yasuyoshi Ouchi, Séverine Kirchner, Bruce Blumberg, and Satoshi Inoue

understand the roles of SXR/PXR in the bone tissue more precisely. Our results demonstrated that loss of SXR/PXR enhanced bone resorption and reduced bone formation in the trabecular bones and decreased thickness in the cortical bones. Moreover, these mice

Free access

R Hardy and M S Cooper

bone remodelling cycle. Inflammatory disease can increase bone resorption, decrease bone formation but most commonly impacts on both of these processes. This review will illustrate these interactions between inflammation and bone metabolism and discuss

Free access

Chalida Nakalekha, Chieko Yokoyama, Hiroyuki Miura, Neil Alles, Kazuhiro Aoki, Keiichi Ohya, and Ikuo Morita

adult PGIS −/− mice, both bone formation and bone resorption parameters were increased ( Fig. 4 A–G). To determine whether the increase in trabecular bone mass was due to an acceleration in bone formation, a dynamic histomorphometric analysis was

Open access

Thomas Funck-Brentano, Karin H Nilsson, Robert Brommage, Petra Henning, Ulf H Lerner, Antti Koskela, Juha Tuukkanen, Martine Cohen-Solal, Sofia Movérare-Skrtic, and Claes Ohlsson

rate was unaffected ( P  = 0.881; Fig. 3D ). The reduced periosteal bone formation and increased endocortical bone resorption were supported by the observation that Alpl mRNA levels ( P  = 0.032) were reduced while Ctsk mRNA levels ( P  < 0

Free access

Idris Mohamed and James K Yeh

resorption parameter were decreasing during this rapid-growth stage. L treatment resulted in a significant increase in the periosteal MAR, BFR/BS, endocortical MS/BS, MAR, BFR/BS, and the ErS/BS (%), while A had no significant effect on bone formation

Open access

J Jeyabalan, M Shah, B Viollet, J P Roux, P Chavassieux, M Korbonits, and C Chenu

). The relationship between AMPK activation and bone resorption is also unclear. Activation of AMPK was shown to inhibit osteoclast formation and bone resorption in vitro , AMPK acting as a negative regulator of RANKL ( Lee et al . 2010 ). By contrast

Free access

Russell T Turner, Kenneth A Philbrick, Carmen P Wong, Dawn A Olson, Adam J Branscum, and Urszula T Iwaniec

-deficient mice and leptin-receptor-deficient mice and rats have reduced overall bone mass, reduced longitudinal bone growth ( Steppan et al . 2000 , Kishida et al . 2005 ), and decreased bone formation ( Gat-Yablonski & Phillip 2008 ). In addition, impaired

Free access

Wang Xiao, Fei Beibei, Shen Guangsi, Jiang Yu, Zhang Wen, Huang Xi, and Xu Youjia

Significant difference with Con group ( P <0.05). Figure 2 Micro-CT three-dimensional reconstruction images and evaluation of oxidative stress, bone resorption, and bone formation markers in vivo . (A) Micro-CT images of mice belonging to the Con, F, OVX, and

Open access

Vikte Lionikaite, Karin L Gustafsson, Anna Westerlund, Sara H Windahl, Antti Koskela, Juha Tuukkanen, Helena Johansson, Claes Ohlsson, H Herschel Conaway, Petra Henning, and Ulf H Lerner

in long bones as well as in vertebra, paying special attention to osteoclastic bone resorption and osteoblastic bone formation. Materials and methods Animals and study design All animal experimental procedures were approved by the Ethics

Free access

Isabel R Orriss, Dilek Guneri, Mark O R Hajjawi, Kristy Shaw, Jessal J Patel, and Timothy R Arnett

until analysis. Levels of the bone formation marker, N-terminal propeptide of type I collagen (P1NP) and the bone resorption marker, cross-linked C-telopeptide (CTX), were assayed using the P1NP and RatLaps ELISAs, respectively (Immunodiagnostics Systems